From liver fat to full-blown metabolic disorder: the kidney as target organ

References

[1] Ludwig J,McGill DB.Nonalcoholic steatohepatitis: Mayo Clinic experience with an hitherto unnamed disease.Mayo Clin Proc1980;55:434-8

[2] Karlsen TH,Zelber-sagi S.The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.The Lancet2022;399:61-116

[3] Wong RJ,Cheung R.Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.Gastroenterology2015;148:547-55

[4] Younossi ZM,Ong J.Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States.Clin Gastroenterol Hepatol2021;19:580-589

[5] Vitale A,Ortolani A.Italian Liver Cancer (ITA.LI.CA) group. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.Gut2022;gutjnl-2021-324915:

[6] Our World in Data. Obesity 2022. Available from: https://ourworldindata.org/obesity [Last accessed on 4 Jul 2022]

[7] International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels, Belgium: International Diabetes Federation; 2021. Available from: https://suckhoenoitiet.vn/download/Atla-benh-dai-thao-duong-2-1511669800.pdf [Last accessed on 4 Jul 2022]

[8] GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019.The Lancet2020;396:1223-49 PMCID:PMC7566194

[9] Marchesini G,Bianchi G.Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.Diabetes2001;50:1844-50

[10] Yki-järvinen H.nonalcholic fatty liver disease as a cause and a consequence of metabolic syndrome.Lancet Diabetes Endocrinol2014;2:901-10

[11] Mantovani A,Beatrice G.nonalcholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.Gut2022;71:156-62

[12] Musso G,Tabibian JH.Association of nonalcholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis.PLoS Med2014;11:e1001680 PMCID:PMC4106719

[13] Mantovani A,Byrne CD.Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis.Metabolism2018;79:64-76

[14] Taylor R.Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause.Diabetologia2008;51:1781-9

[15] Tushuizen ME,Pouwels PJ.Pancreatic fat content and beta-cell function in men with and without type 2 diabetes.Diabetes Care2007;30:2916-21

[16] Taylor R,Zhyzhneuskaya S.Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for β cell recovery.Cell Metab2018;28:547-556

[17] Lean ME,Barnes AC.Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial.The Lancet2018;391:541-51

[18] Go AS,Fan D,Hsu CY.Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.N Engl J Med2004;351:1296-305

[19] Association for the Study of the Liver (EASL)., European Association for the Study of Diabetes (EASD)., European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of nonalcholic fatty liver disease.Obes Facts2016;9:65-90

[20] Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO)., Members of the guidelines panel., Coordinator., AISF Members., SID Members., SIO Members., Metodologists. nonalcholic fatty liver disease in adults 2021: a clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).Dig Liver Dis2022;54:170-82

[21] Francque SM,Kautz A.nonalcholic fatty liver disease: a patient guideline.JHEP Rep2021;3:100322 PMCID:PMC8514420

[22] Palmer SC,Mustafa RA.Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.BMJ2022;376:o109 PMCID:PMC8764512

[23] Jastreboff AM,Ahmad NN.Tirzepatide once weekly for the treatment of obesity.N Engl J Med2022 (in press).;

[24] Wilding JPH,Calanna S.STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity.N Engl J Med2021;384:989-1002

[25] Kovesdy CP,Zoccali C.Obesity and kidney disease: hidden consequences of the epidemic.J Bras Nefrol2017;39:1-10

[26] Petroni ML,Colosimo S,Mazzotti A.Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: a retrospective cohort study.Endocrinol Diabetes Metab2019;2:e00082 PMCID:PMC6775466